Trial Profile
Phase I trial of AKB 6899 in patients with cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs AKB 6899 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Akebia Therapeutics
- 23 May 2016 According to an Akebia Therapeutics media release, the company expected to commence clinical development of AKB-6899 in 2016.
- 14 Mar 2016 According to an Akebia Therapeutics media release, the company has opened an Investigative New Drug Application with the US FDA for AKB-6899 for treatment of cancer.
- 04 Jan 2016 According to an Akebia Therapeutics media release, this trial is expected to being in 2016.